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Abstract 
 
Objectives 
The intravenous injection of bisphosphonates, currently used for osteoporosis, myeloma or bone 
metastases, can cause ONJ especially in consequence of trauma. In order to avoid trauma during 
bisphosphonate treatment, preventive oral surgery is recommended. 
The research aimed to evidence whether inflammatory and osteoclastogenic factors are not induced 
in oral mucosa after bisphosphonate treatment in patients receiving oral preventive surgery 
procedure, and whether proliferation factors are not inhibited. 
Patients and Methods 
Specimens of oral mucosa were removed from healthy subjects and from patients undergoing 
preventive oral surgery before bisphosphonate treatment. The expression of cytokines, factors 
involved in osteoclast activity, in cell proliferation and angiogenesis were examined. 
Results 
Cytokines and RANK-L levels decreased significantly in mucosa from patients undergoing 
preventive oral surgery procedure before bisphosphonate treatment in comparison with their levels 
at the beginning of procedure and also in comparison with the level in patients treated only with 
bisphosphonates and not developing ONJ; conversely, osteoprotegerin and hydroxymethylglutaryl 
coenzyme A reductase significantly increased or not changed. 
Conclusions 
The results suggest that preventive oral surgery could be able to prevent ONJ due to bisphosphonate 
treatment: the mucosa is not stimulated by bisphosphonates to cause ONJ, since bisphosphonates 
are probably not released from the bone. 
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Introduction 
 
Bisphosphonates (BP) are used in treating patients bearing solid tumors or myelomas, to reduce 
skeletal alterations due to bone metastasis. They are thus increasingly incorporated in oncologic 
treatments aimed at improving the quality of life. In 2003, an association between BP use and 
osteonecrosis of the jaw (ONJ) in oncologic patients was reported (Brotons and Penarrocha, 2003). 
The American Association of Oral and Maxillofacial Surgeons (AAOMS) reported that the 
incidence of ONJ in patients treated with BP in whom this therapy is associated with dental 
extractions and/or oral surgery procedures ranges from 0.8 to 12% (Advisory Task Force on 
Bisphosphonate-Related Ostenonecrosis of the Jaws, 2007; Marx, 2007). ONJ is a chronic 
complication of BP therapy that chiefly occurs when administration is intravenous; the highest 
frequency is in the mandible (Marx, 2003; Wang et al., 2003; Ruggiero et al., 2004). 
In the light of these observations, dental management protocols to be implemented before BP 
administration may be crucial, in order to avoid oral intervention during or after BP treatment. Such 
protocols, eliminating any potential infection sites in patients before BP treatment, aim to ensure an 
adequate oral health status, in order to reduce the need for tooth extraction, and as a consequence, 
the risk of ONJ (Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, 
2007; Rayman et al., 2009). Studies on preventive dental measures have demonstrated a decreased 
incidence of ONJ in patients treated with BP for bone metastases from solid tumors (Ripamonti et 
al., 2009). 
The mechanisms underlying ONJ are not fully understood. Recent studies have suggested 
involvement of the mucosa in this syndrome (Mozzati et al., 2013; Morris and Cruickshank, 2010; 
Silverman and Landesberg, 2009). In patients treated for at least 12 months with zoledronic acid, a 
third-generation BP containing nitrogen, the mucosa produced inflammatory factors and factors 
stimulating osteoclasts, in those cases in which ONJ subsequently developed (Mozzati et al., 2013). 
The possible involvement of the mucosa was confirmed using an “in vitro” model, since the ”in 
vivo” observations did not fully elucidate the interactions between soft-tissues and bone that lead to 
ONJ (Saracino et al., 2012). The “in vitro” model consisted of epithelial cells exposed to zoledronic 
acid, and osteoblasts grown in a culture medium conditioned by epithelial cells treated with 
zoledronic acid. The results showed that treatment of epithelial cells with zoledronic acid reduced 
cell proliferation, suggesting that this treatment may decrease cells’ healing ability after injury. 
Moreover, zoledronic acid increased the release in the culture medium of pro-inflammatory 
cytokines, such as TNFα, and decreased cell content of PPARα, a member of the nuclear hormone 
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receptor superfamily that plays a beneficial role in reducing inflammation. In turn, when this 
medium rich in pro-inflammatory cytokines was used to grow osteoblasts, it affected their 
proliferation, possibly reducing the regenerate capability of the bone; it also increased expression of 
RANK-L, which is a factor involved in stimulating osteoclast differentiation (Saracino et al., 2012). 
In the light of the probable importance of epithelial cells in inducing ONJ after treatment with BP, 
and of the importance of adopting preventive measures before administration of these drugs, in 
order to avoid any trauma that may trigger ONJ, the present study examined the mucosa of patients 
before the preventive oral surgery and the administration of zoledronic acid, and after the 
intravenous administration of the BP. 
 
Patients and Methods 
 
Patients  
Eleven patients (group A) with bone metastases from solid tumors or multiple myeloma, waiting for 
therapeutic treatment with intravenous zoledronic acid, and 11 healthy subjects, entered the study. 
The patients received 4 mg intravenous zoledronic acid (Zometa®; Novartis Pharma SpA, Basel, 
Switzerland) every 4 weeks for 12 months; they did not receive radiotherapy at the head and neck 
region, nor any chemotherapeutical medications during zoledronic acid treatment. Informed consent 
was obtained from all patients. The study protocol was approved by the Ethics Committee of Turin 
University (local ethical board approval number: CEI/396; protocol number: 0010469). Patients 
treated with BP for osteoporosis were excluded. 
At their inclusion in the trial, the patients were registered in a computerized clinical file, which 
recorded information on age, sex, smoking habits, alcohol consumption, systemic pathologies and 
the use of any drugs. Each patients was subjected to a periodontal evalutation by PSR code 
(periodontal screening and recording): all patients had a PSR score between 0 and 2. 
Afterwards, each patient attended a program of professional dental hygiene to nullify differences in 
preoperative hygiene conditions. 
Before treatment with zoledronic acid, the patients of group A underwent an oral preventive surgery 
to remove any potential infection sites. 
During zoledronic acid administration, all the patients were observed for the absence or presence of 
ONJ. 
 
Oral Preventive Surgical Procedure  
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In the group A patients, extraction of only one tooth was performed under locoregional anaesthesia 
(3% mepivacaine with 1:100,000 epinephrine), and was performed atraumatically, without 
elevation of full-thickness flaps; healing was natural, by clot formation. In all cases, vycril 4/0 
sutures were used to suture the soft tissue and removed after 7 days. No other preventive surgery 
was done. Patients were given antibiotic (amoxicillin every 8 hours for 6 days) and oral anti-
inflammatory treatment (Ibuprofen every 12 hours for 3 days).  
 
Mucosa specimens 
Mucosa specimens were taken from an area corresponding to the maxillary protuberance, from 
healthy subjects, and from group A patients before tooth extraction (time A1) and one month after 
the completion of the treatment with zoledronic acid (time A2). Excision was half-thickness, to 
avoid removing the periosteum and exposing the bone. A simple suture was placed. All specimens 
were placed in RNA Later solution (Qiagen, Milan, Italy), and maintained at –80°C until use. The 
values obtained at A2 time have been compared with those obtained in patients who did not 
undergo preventive oral surgical procedure, treated with zoledronic acid, but without the presence 
of ONJ (ONJ-) (values previously published) (Mozzati et al., 2013). 
 
Radiographic analysis 
Patients were monitored through dental panoramic radiography and computed tomography (CT), to 
evaluate the presence or absence of ONJ. 
 
Biological factor analysis 
Mucosa specimens were analyzed to determine expression of inflammatory (IL-1β, IL-6, IL-8 and 
TNFα), osteoclastogenic (RANK-L and osteoprotegerin, OPG), proliferation (3-hydroxy-3-methyl-
glutaryl-CoA reductase, HMGR) and angiogenetic (VEGF) parameters, using real-time polymerase 
chain reaction (PCR). 
Total RNA was extracted from specimens using the NucleoSpin RNA II Kit (Macherey-Nagel 
GmbH & Co. KG, Düren, Germany), as reported elsewhere (Mozzati et al., 2011). Real-time PCR 
was run with single-stranded cDNA prepared from total RNA (1 µg) using a High-Capacity cDNA 
Archive kit (Applied Bio Systems, Foster City, CA). 
The forward (FW) and reverse (RV) primers were designed using Beacon Designer® software 
(Bio-Rad, Hercules, CA). Twenty-five µl of a PCR mixture containing cDNA template equivalent 
to 40 ng of total RNA, 5 pmoles each of forward and reverse primers, and 2× IQ SYBR Green 
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SuperMix (Bio-Rad, Hercules, CA) were amplified using an iCycler PCR instrument (Bio-Rad, 
Hercules, CA) as previously reported (Mozzati et al., 2013). Each sample was tested in duplicate, 
and threshold cycle (Ct) values from each reaction were averaged. GAPDH was used as house-
keeping gene. The changes in expression were defined as those detected in the mucosa specimens 
taken from patients at times A1 or A2, versus those detected in the mucosa specimens taken from 
healthy subjects, and were calculated as 2-∆∆Ct, where ∆Ct = Ctsample - CtGAPDH and 
∆∆Ct = ∆CtT sample - ∆CtTnormal.  
 
Statistical analysis 
Statistical analysis was performed using the GraphPad Instat software package. For each biological 
factor examined, differences between the mean values of the two mucosa specimens, A1 and A2, 
taken before and after treatment with zoledronic acid, were assessed using the paired t-test. 
Differences between the mean values of specimens A2, and those of ONJ-, were assessed using the 
Mann-Whitney Test. Differences were taken as being statistically significant for p<0.05. 
 
 
Results 
 
Patients 
Group A enrolled 11 patients: 7 men (64%) and 4 women (36%) with mean age of 58 ± 9 years. 5 
patients had multiple myeloma (46%), 3 had prostatic carcinoma (27%) and 3 had lung carcinoma 
(27%). All patients underwent a surgical procedure to remove only one tooth. The BP treatment 
started 30 days after tooth extraction, when the mucosa of extraction socket was completely healed 
in all patients. 
 
Radiographic analysis 
The patients enrolled were monitored through dental panoramic radiography followed by the more 
informative CT imaging. This is in line with previous findings (Bianchi et al., 2007). Having 
undergone preventive oral surgery before zoledronic acid administration, no patient showed any 
signs of ONJ as evidenced by both dental panoramic radiography and CT imaging (data not shown). 
 
Biological factor analysis 
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Expression of the biological factors involved in the inflammatory process, IL-1β, IL-6, IL-8 and 
TNFα, is shown in Figure 1. Levels of all cytokines varied in the mucosa specimens taken before 
versus those taken after administration of zoledronic acid, with the exception of TNFα, which was 
similar at the two times. Cytokine levels, referred to values found for healthy subjects taken as 1, 
were found to be lower in specimens taken after administration of zoledronic acid (time A2) than in 
those taken before zoledronic acid administration (time A1). 
Figure 2 shows the variation of RANK-L and OPG between specimens of mucosa taken before and 
after administration of zoledronic acid. RANK-L was decreased in mucosa specimens taken after 
zoledronic acid administration versus those taken before administration. Conversely, OPG did not 
differ before and after zoledronic acid administration. 
As regards factors involved in cell proliferation (HMGR) and in endothelial cell proliferation 
(VEGF), Figure 2 also shows that HMGR increased in the mucosa after zoledronic acid 
administration, versus mucosa taken before the preventive oral surgery and administration of 
zoledronic acid, whereas VEGF showed no variation.. 
Our previous research [9] investigated the same parameters in the mucosa taken after treatment with 
zoledronic acid from patients not undergoing the preventive oral surgery, who did or did not go on 
to develop ONJ. To confirm the beneficial effect of the preventive oral surgery, the values of the 
various parameters obtained from the mucosa of patients who had undergone the preventive surgery 
protocol followed by administration of zoledronic acid (time A2) were compared to the 
corresponding values obtained from the mucosa of patients treated with zoledronic acid without 
prior preventive oral surgery, and who showed no signs of ONJ (ONJ-). Figure 3 shows that all 
inflammatory parameters in mucosa from patients at timeA2, with the exception of TNFα, had 
values lower than those observed in the ONJ- patients. Similarly, Figure 4 shows that the values of 
parameters relating to osteoclast differentiation are lower in patients at time A2 in comparison with 
those of the ONJ- patients. As regards the angiogenesis and proliferation parameters, VEGF was 
lower in time A2 specimens than in ONJ- specimens, whereas HMGR values were unchanged. 
 
 
Discussion 
 
The study aimed to evaluate the beneficial effect of a preventive oral surgery in patients who are 
scheduled for treatment with BP, for bone metastases from solid tumors or for myeloma. The 
efficacy of BP has been demonstrated in clinical trials, in which they were administered by 
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intravenous injection (Pavlakis et al., 2005); Aapro et al., 2008). However, the use of BP in 
oncology is sometimes accompanied by an adverse effect, namely the development of ONJ. This 
side effect can negatively affect the patient’s quality of life (La Verde et al., 2008; Ruggiero et al., 
2006). ONJ may develop during invasive dental interventions (Vandone et al., 2011) or in an 
apparently spontaneous manner (Lo et al., 2010). It appears probable that trauma, even if minor, is 
always the cause of ONJ. Since no alternative therapy is currently available for patients with 
metastatic bone disease, a possible approach is to remove any potential infection sites in patients 
before BP treatment, in an effort to guarantee an adequate oral health status and reduce the risk of 
ONJ (Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, 2007; Rayman 
et al., 2009). It was thus felt to be important to evaluate, alongside clinical and radiography 
observations, inflammatory, osteoclastogenic, angiogenesis and cell proliferation parameters, so as 
to verify the beneficial effects of a preventive oral surgery, applied prior to administration of 
zoledronic acid. Specimens of mucosa were taken from patients at two time-points, in order to 
identify any differences in gene expression before the preventive surgery and zoledronic acid 
treatment (time A1), and after 12 months of zoledronic acid treatment (time A2). Moreover, the 
results obtained at time A2 were also compared with specimens from patients treated with 
zoledronic acid who had not undergoing the preventive surgery protocol, and who did not go on to 
develop ONJ. 
It is noteworthy that, at time A2, patients showed no signs of ONJ after 12 months of zoledronic 
acid treatment, and that lower levels of the inflammatory and osteoclastogenic factors were 
produced by the mucosa than at time A1. This decrease, or lack of change, in inflammatory factors 
is in contrast with findings that zoledronic acid causes an inflammatory acute-phase response 
(Russell et al., 1999); this response due to cytokine production is maximal within 28–36 h after 
intravenous administration, and disappears 2–3 days later, despite continuing treatment (Santini et 
al., 2007). The different results we obtained may be due to the fact that, in this study, specimens of 
mucosa were taken one month after the 12th dose of zoledronic acid. Our results seem to suggest 
that the decreased IL-6 expression is correlated, as well as with a general decrease in the 
inflammatory response, also with the decreased osteoclast activity, as demonstrated by the 
decreased RANK-L expression. In fact, IL-6 is considered to be an osteoclastogenic cytokine, 
important in inducing bone loss (Rufo et al., 2011; Jimi et al., 2010). Moreover, it has been reported 
that induction of IL-6 due to pro-inflammatory stimuli is also accompanied by down-regulation of 
markers of osteoblastic differentiation (Kraus et al., 2011; Krishnan et al., 2011), and thus its 
decrease allows osteoblasts to engage in osteogenic action. 
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Unlike IL-6, HMGR expression did not change at time A2in comparison with time A1; this might 
be significant, because this enzyme is important in the synthesis of cholesterol and isoprenoids. 
Cholesterol at physiological concentrations is crucial for osteoblastic differentiation (Viccica et al., 
2007), and isoprenoids are involved in the isoprenylation of some proteins, such as ras, involved in 
regulating cell proliferation (Cho and Lee, 2002). The accumulation of unprenylated proteins via 
downregulation of HMGR is believed to largely account for the cytotoxic effects of zoledronic acid 
Raikkonen J et al., 2010). In a previous paper we also reported that, in mucosa taken from patients 
with ONJ, the mRNA content of HMGR was lower than in that of the patients without ONJ 
(Mozzati et al., 2013). Moreover, the “ in vitro” treatment of epithelial cells with zoledronic acid 
caused a decreased HMGR expression (Saracino et al., 20112). 
The results reported here could partially explain why BP induce osteoclast activity and bone 
necrosis in the jaw, but not in other bones, where BP inhibit osteoclast activity in order to reduce 
bone loss: BPs are known to accumulate in the bone, and may be released from the bone into the 
surrounding tissues in response to minor traumas (dentures or dental prostheses, caries and 
periodontal disease) (Woo et al., 2006). In the case of the jaw, the tissue concerned is the mucosa, 
where epithelial cells, fibroblasts and lymphocytes are present. In this context, BP inhibit HMGR, 
and induce these cells to produce cytokines. If ONJ is to be prevented, such trauma must if at all 
possible be avoided; this can be facilitated by means of preventive surgical treatment to eliminate 
possible sources of infection. 
The reduction of VEGF production in mucosa specimens after treatment with zoledronic acid, 
found here, could be explained by the fact that preventive surgical treatment is unable to prevent the 
antiangiogenic effect of BP, but this effect is not in itself enough to cause the development of ONJ. 
At the present, contrasting results have been reported about the effect of BP on angiogenesis, as it 
relates to ONJ development. (Landesberg et al., 2011; Rustemeyer and Bremerich, 2010). 
The comparison between mucosa from patients treated with oral preventive surgery before 
zoledronic acid treatment, and mucosa from patients receiving zoledronic acid alone who did not 
develop ONJ, showed that cytokines and osteoclast-stimulating factor levels were lower in the 
former group than in the latter group. This confirms that preventive oral surgery before BP 
administration is a good practice. 
In conclusion, preventive oral surgery could be able to prevent ONJ due to zoledronic acid 
treatment: the mucosa is not stimulated by BP to cause ONJ, since BP are probably not released 
from the bone, in consequence of lack of trauma after zoledronic acid treatment. The decrease in IL-
6 leads to decreased osteoclastogenic activity, evidenced by the decreased RANK-L: increased 
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HMGR levels are conducive of good proliferative ability. Further studies with a long-term follow-
up and with larger number of patients will be necessary to confirm the results of this study, that is 
that preventive oral surgery is fundamental to prevent ONJ. 
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Figure Legends 
 
Figure 1 
mRNA content of IL-1β, IL-6, IL-8, TNFα in the mucosa taken from patients before preventive oral 
surgery (time A1) and after  zoledronic acid administration (time A2) 
The data are means ± S.D. of values obtained from the mucosa of 11 patients of group A, and are 
expressed as fold increase determined as described in the patients and methods section. 
* paired t-test, p<0.05 time A2 versus time A1 
Abbreviations: A1, time A1; A2, time A2 
 
Figure 2 
mRNA content of RANK-L, OPG, VEGF, HMGR in the mucosa taken from patients before 
preventive oral surgery (time A1) and after  zoledronic acid administration (time A2) 
The data are means ± S.D. of values obtained from mucosa of 11 patients of group A and are 
expressed as fold increase determined as in the patients and methods section. 
* paired t-test, p<0.05 time A2 versus time A1 
Abbreviations: A1, time A1; A2, time A2 
 
Figure 3 
mRNA content of IL-1β, IL-6, IL-8, TNFα in the mucosa taken from patients not receiving the 
preventive surgery treatment and free of ONJ after zoledronic acid administration (ONJ-), and from 
patients receiving preventive oral surgery followed by zoledronic acid administration (time A2) 
The data are means ± S.D. of values obtained from mucosa of 16 patients for ONJ- and 11 patients 
for A group and are expressed as fold increase determined as described in the patients and methods 
section. 
* Mann-Whitney Test, p<0.05 time A2versus ONJ- 
 
Figure 4 
mRNA content of RANK-L, OPG, VEGF, HMGR in the mucosa taken from patients not receiving 
preventive surgery treatment, and free of ONJ after zoledronic acid administration (ONJ-) and from 
patients receiving the preventive oral surgery followed by zoledronic acid administration (A2). 
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The data are means ± S.D. of values obtained from mucosa of 16 patients for ONJ- and 11 patients 
for A group and are expressed as fold increase determined as described in the patients and methods 
section. 
* Mann-Whitney Test,p<0.05 time A2versus ONJ- 




